Company Overview
AN2 Therapeutics, Inc. operates as a biopharmaceutical entity dedicated to the discovery and development of novel small molecule therapeutics, with its initial clinical candidate, epetraborole, currently advancing through phase 3 clinical trials for the treatment of non-tuberculous mycobacterial lung disease. The company functions within the healthcare sector and specifically the biotechnology industry, a landscape characterized by significant research and development expenditures and regulatory scrutiny regarding novel drug candidates. As of the latest data, the organization employs 21 individuals and holds a market capitalization of $131.54M. The annual revenue is not available for disclosure, and the absence of reported revenue figures alongside the current market cap indicates that the company's valuation is primarily driven by its asset pipeline and future potential rather than current commercial sales. This financial structure is typical for early-stage biotechnology firms where significant capital is allocated to clinical development before product launch, resulting in a market cap that reflects investor sentiment on future clinical success rather than current profitability.
Financial Health
The company reported a net income of $-35,174,000 over the trailing twelve months, while revenue and EBITDA figures are not available for public reporting. The substantial negative net income relative to the lack of reported revenue highlights a cost structure dominated by high research and development expenses and clinical trial costs, which are standard for biotechnology firms in the development phase. Free cash flow stands at $-18,382,124, indicating that the company is consuming cash to fund its operations and development programs, which limits immediate financial flexibility but is a necessary expenditure for advancing clinical candidates. All three reported margins—gross margin, operating margin, and profit margin—are recorded at 0.0%, a metric that reflects the company's current lack of commercial revenue generation and the fact that all expenses exceed the minimal or zero revenue base. The balance sheet shows a cash position of $58.00M with no reported debt, resulting in a debt-to-equity ratio that is not available due to the absence of debt figures. This liquidity profile suggests a conservative balance sheet regarding leverage, as the company relies entirely on equity financing rather than debt to fund its operations. The current ratio is 6.87, a figure that signifies strong short-term liquidity and the ability to cover short-term obligations with current assets, providing a buffer against the cash burn associated with clinical trials. Furthermore, the return on equity is -52.1% and the return on assets is -30.9%, metrics that reveal that the company is currently diluting shareholder value and utilizing assets to generate losses rather than profits, a common characteristic of pre-revenue biotechnology companies.
Valuation Assessment
The trailing P/E ratio is not available due to the lack of earnings, while the forward P/E is listed as -4.58, a negative figure that implies the market expects future earnings to be negative or that the current valuation model relies on alternative metrics given the company's unprofitability. The price-to-book ratio is 1.89, indicating that the market values the company at a premium of 89% over its book value, which suggests investors are pricing in significant future potential from the epetraborole candidate despite current losses. Alternative valuation metrics such as the price-to-sales ratio and EV/EBITDA are not available, which prevents a direct comparison to traditional valuation multiples and suggests that investors are relying on clinical trial data and market cap to assess value. The stock has traded between a 52-week high of $6.91 and a 52-week low of $1.00, creating a wide trading range that reflects high volatility typical of small-cap biotechnology stocks dependent on clinical trial outcomes. The beta value is recorded as -0.03, a negative figure that is anomalous for equities and suggests an inverse or negligible correlation to the broader market movements, likely resulting from data anomalies or extreme idiosyncratic trading patterns specific to this small-cap issuer.
Growth & Income
The revenue growth and earnings growth rates over the year-over-year period are not available for disclosure, preventing a direct comparison of growth trajectories between top-line sales and bottom-line profitability. The company does not pay a dividend, evidenced by a dividend yield that is not available and a payout ratio of 0.0%, which confirms that the organization retains all available cash flow to reinvest into research and development activities rather than distributing income to shareholders. The 0.0% payout ratio is sustainable in the context of a non-dividend payer, as the company prioritizes capital allocation toward advancing its clinical pipeline over returning capital to investors. Consequently, the overall growth and income profile is defined by capital retention and clinical development rather than dividend income or established revenue growth, focusing entirely on the potential future value creation from the phase 3 clinical trial candidate.